Outcomes in COVID-19 acebilustat studies

0 0.5 1 1.5+ All studies 0% 1 120 Improvement, Studies, Patients Relative Risk Hospitalization 0% 1 120 RCTs 0% 1 120 Early 0% 1 120 Acebilustat for COVID-19 c19early.org November 2025 Favorsacebilustat Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Levitt (DB RCT) 0% 1.00 [0.06-15.6] hosp. 1/60 1/60 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Early treatment 0% 1.00 [0.06-15.6] 1/60 1/60 no change All studies 0% 1.00 [0.06-15.6] 1/60 1/60 no change 1 acebilustat COVID-19 study c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 1. Effect extraction pre-specified(most serious outcome) Favors acebilustat Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Levitt (DB RCT) 0% 1.00 [0.06-15.6] hosp. 1/60 1/60 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Early treatment 0% 1.00 [0.06-15.6] 1/60 1/60 no change All studies 0% 1.00 [0.06-15.6] 1/60 1/60 no change 1 acebilustat COVID-19 hospitalization result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 1. Favors acebilustat Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Levitt (DB RCT) 0% 1.00 [0.06-15.6] hosp. 1/60 1/60 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Early treatment 0% 1.00 [0.06-15.6] 1/60 1/60 no change All studies 0% 1.00 [0.06-15.6] 1/60 1/60 no change 1 acebilustat COVID-19 serious outcome c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 1. Effect extraction pre-specified(most serious outcome) Favors acebilustat Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Levitt (DB RCT) -67% 1.67 [0.96-2.94] no recov. 60 (n) 60 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.07 Early treatment -67% 1.67 [0.96-2.94] 60 (n) 60 (n) 67% higher risk All studies -67% 1.67 [0.96-2.94] 60 (n) 60 (n) 67% higher risk 1 acebilustat COVID-19 recovery result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.07 Favors acebilustat Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Levitt (DB RCT) 0% 1.00 [0.06-15.6] hosp. 1/60 1/60 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Early treatment 0% 1.00 [0.06-15.6] 1/60 1/60 no change All studies 0% 1.00 [0.06-15.6] 1/60 1/60 no change 1 acebilustat COVID-19 Randomized Controlled Trial c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 1. Effect extraction pre-specified(most serious outcome) Favors acebilustat Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Levitt (DB RCT) 0% 1.00 [0.06-15.6] hosp. 1/60 1/60 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Early treatment 0% 1.00 [0.06-15.6] 1/60 1/60 no change All studies 0% 1.00 [0.06-15.6] 1/60 1/60 no change 1 acebilustat COVID-19 peer reviewed studies c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 1. Effect extraction pre-specified(most serious outcome) Favors acebilustat Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Levitt (DB RCT) 0% 1.00 [0.06-15.6] hosp. 1/60 1/60 Improvement, RR [CI] Treatment Control Levitt (DB RCT) 80% 0.20 [0.02-1.66] progression 1/60 5/60 Levitt (DB RCT) -67% 1.67 [0.96-2.94] no recov. 60 (n) 60 (n) Levitt (DB RCT) -61% 1.61 [0.99-2.63] no recov. 60 (n) 60 (n) Acebilustat COVID-19 outcomes c19early.org November 2025 Favors acebilustat Favors control